Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG is conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease. The study aims to evaluate the effectiveness and safety of finerenone in slowing the progression of non-diabetic chronic kidney disease (CKD) compared to a placebo. This research is significant as it seeks to provide a new treatment option for CKD patients who do not have diabetes.
The intervention being tested is finerenone, a drug designed to block aldosterone, a hormone that can cause kidney and heart damage. Participants will receive either finerenone or a placebo, both administered as daily oral tablets, alongside their current CKD medication.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. This means participants are randomly assigned to either the finerenone or placebo group, and neither the participants nor the investigators know which treatment is being administered. The primary purpose of the study is treatment-focused.
The study began on September 21, 2021, and is currently active but not recruiting new participants. The last update was submitted on August 5, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
From a market perspective, the successful development of finerenone could positively impact Bayer’s stock performance by expanding its product portfolio in the CKD treatment market. This could also influence investor sentiment positively, especially if the drug proves to be a viable treatment option compared to existing therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.